My Stocks Explore Events Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Live today
{{event.ticker}} @{{event.event_utc_datetime | date:'h:mm a'}}
{{market.market_short_name}} {{market.last_price | number : 2}}
AlphaStreet

Want to join the conversation?


$DVA {{ '2016-02-11T22:34:14+0000' | timeago}} • Webcast

Denver, Colorado-based $DVA said that most of the company's growth internationally have been through acquisitions. In Kidney Care, the company's strategic position in US is strong. In 4Q15, the company recorded an estimated accrual of $23MM for potential damages and liabilities in its DaVita Rx pharmacy business.

User Jasmin Crosswhite {{ '2017-01-24T20:22:04+0000' | timeago}}

$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?

User ritesh salot {{ '2017-01-24T14:22:47+0000' | timeago}}

Baba

User Robert Smith {{ '2017-01-24T13:01:54+0000' | timeago}}

$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?

User Charles Elliston {{ '2017-01-23T20:14:24+0000' | timeago}}

A federal judge has upheld the DOJ’s decision to block the $AET-$HUM merger.

User Josh Allan {{ '2017-01-23T20:10:30+0000' | timeago}}

$YHOO is reporting today after market close. Nobody cares about this stock.

$COF {{ '2017-01-24T21:34:28+0000' | timeago}} • Announcement

$COF reported a lower profit in 4Q16, hurt by higher provision for credit losses. Net income dropped 14% to $791MM or $1.45 per share. The company recorded a charge of $72MM consisting of a build in the the U.K. Payment Protection Insurance customer refund reserve and an impairment associated with certain acquired intangible and software assets.

$SYK {{ '2017-01-24T21:30:30+0000' | timeago}} • Announcement

Medical technology company $SYK reported a decrease in 4Q16 earnings. Net earnings decreased 2.3% to $510MM and diluted EPS decreased 2.9% to $1.34 compared to 4Q15. Consolidated net sales of $3.2Bil increased 16.2% in 4Q16 versus last year.

$ISRG {{ '2017-01-24T21:28:33+0000' | timeago}} • Announcement

For 3Q16, $ISRG's Instruments and Accessories revenue rose 18.64% YoverY to $386.3MM, helped by growth in U.S. general surgery procedures and worldwide urologic procedures. Service revenue grew by 12.06% to $134.7MM, while Systems revenue for the quarter rose by 2.25% to $235.9MM from a year ago.

$ISRG {{ '2017-01-24T21:23:55+0000' | timeago}} • Announcement

Medical devices company $ISRG posted higher 4Q16 earnings, helped by higher revenue. Net income for the quarter rose 7.36% to $204MM or $5.13 per share from $190MM or $4.99 per share a year ago. Revenue grew 11.88% YoverY to $756.9MM. Excluding items, $ISRG earned $6.09 per share.

$STX {{ '2017-01-24T21:20:36+0000' | timeago}} • Announcement

Looking ahead, $STX said it is optimistic about the long-term opportunities for the company's business as enterprises and consumers embrace and benefit from the shift of storage to cloud and mobile applications.